eyestock logo

eyestock

CA

CalciMedica IncNASDAQ CALC

Последний отчетный период 30 июня, 2024

Обновлено 23 дек., 2024

Последняя цена

Капитализация млрд. $

0.046

Micro

Биржа

XNAS - Nasdaq

Анализ акций CALC

CA

Нет оценки

Количественный анализ Eyestock не покрывает акции CalciMedica Inc.

Капитализация млрд. $

0.046

Дивидендная доходность

Оборот

10.75 млрд

Сайт компании

https://calcimedica.com/

CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

Смотреть Секцию: Рейтинг